Widespread genome transcription: New possibilities for RNA therapies

Biochemical and Biophysical Research Communications

Volumn 452, Issue 2, 2014, Pages 294-301

  Takahashi, Hazuki ^a   Carninci, Piero ^a  

^a RIKEN   (Japan)

Author keywords

Antisense; Antiviral therapy; Gene therapy; Non coding RNA; SINEUP

Indexed keywords

COMPLEMENTARY RNA; LONG UNTRANSLATED RNA; NUCLEIC ACID; UNTRANSLATED RNA;

CELL SPECIFICITY; GENE DELIVERY SYSTEM; GENE THERAPY; GENETIC TRANSCRIPTION; GENOME; HUMAN; NONHUMAN; REVIEW; RNA STABILITY; RNA STRUCTURE; RNA TRANSLATION; STABLE EXPRESSION; VIRUS PATHOGENESIS; ANTISENSE; ANTIVIRAL THERAPY; GENE TARGETING; GENE VECTOR; GENETICS; HUMAN GENOME; METHODOLOGY; NON-CODING RNA; SINEUP;

ANTISENSE; ANTIVIRAL THERAPY; GENE THERAPY; NON-CODING RNA; SINEUP;

GENE TARGETING; GENETIC THERAPY; GENETIC VECTORS; GENOME, HUMAN; HUMANS; RNA, LONG NONCODING; TRANSCRIPTION, GENETIC;

EID: 84908644298     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.08.139     Document Type: Review

References (92)

1. P. Carninci, T. Kasukawa, S. Katayama, et al., The transcriptional landscape of the mammalian genome, Science 309 (2005) 1559-1563.
2. E. Birney, J.A. Stamatoyannopoulos, A. Dutta, et al., Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project, Nature 447 (2007) 799-816.
3. B.E. Bernstein, E. Birney, I. Dunham, E.D. Green, C. Gunter, M. Snyder, An integrated encyclopedia of DNA elements in the human genome, Nature 489 (2012) 57-74.
4. P. Kapranov, J. Cheng, S. Dike, et al., RNA maps reveal new RNA classes and a possible function for pervasive transcription, Science 316 (2007) 1484-1488.
5. T. Derrien, R. Johnson, G. Bussotti, et al., The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression, Genome Res. 22 (2012) 1775-1789.
6. A. Fort, K. Hashimoto, D. Yamada, et al., Deep transcriptome profiling of mammalian stem cells supports a regulatory role for retrotransposons in pluripotency maintenance, Nat. Genet. 46 (2014) 558-566.
7. S. Djebali, C.A. Davis, A. Merkel, et al., Landscape of transcription in human cells, Nature 489 (2012) 101-108.
8. M. Guttman, J. Donaghey, B.W. Carey, et al., LincRNAs act in the circuitry controlling pluripotency and differentiation, Nature 477 (2011) 295-300.
9. J.M. Engreitz, A. Pandya-Jones, P. McDonel, et al., The Xist lncRNA exploits three-dimensional genome architecture to spread across the X chromosome, Science 341 (2013) 1237973.
10. T. Gutschner, S. Diederichs, The hallmarks of cancer: a long non-coding RNA point of view, RNA Biol. 9 (2012) 703-719.
11. E. Yildirim, J.E. Kirby, D.E. Brown, et al., Xist RNA is a potent suppressor of hematologic cancer in mice, Cell 152 (2013) 727-742.
12. J.L. Rinn, M. Kertesz, J.K. Wang, et al., Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs, Cell 129 (2007) 1311-1323.
13. R. Andersson, C. Gebhard, I. Miguel-Escalada, et al., An atlas of active enhancers across human cell types and tissues, Nature 507 (2014) 455-461.
14. F. Lai, U.A. Orom, M. Cesaroni, et al., Activating RNAs associate with Mediator to enhance chromatin architecture and transcription, Nature 494 (2013) 497-501.
15. T. Hirose, G. Virnicchi, A. Tanigawa, et al., NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies, Mol. Biol. Cell 25 (2014) 169-183.
16. J. Krol, I. Loedige, W. Filipowicz, The widespread regulation of microRNA biogenesis, function and decay, Nat. Rev. Genet. 11 (2010) 597-610.
17. C.M. Smith, J.A. Steitz, Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 50′-terminal oligopyrimidine gene family reveals common features of snoRNA host genes, Mol. Cell. Biol. 18 (1998) 6897-6909.
18. P. Carninci, RNA dust: where are the genes?, DNA Res 17 (2010) 51-59.
19. Post-transcriptional processing generates a diversity of 50′-modified long and short RNAs, Nature 457 (2009) 1028-1032.
20. A. Fatica, I. Bozzoni, Long non-coding RNAs: new players in cell differentiation and development, Nat. Rev. Genet. 15 (2014) 7-21.
21. A. Saxena, P. Carninci, Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs, BioEssays 33 (2011) 830-839.
22. P. Carninci, J. Yasuda, Y. Hayashizaki, Multifaceted mammalian transcriptome, Curr. Opin. Cell Biol. 20 (2008) 274-280.
23. K.V. Morris, J.S. Mattick, The rise of regulatory RNA, Nat. Rev. Genet. 15 (2014) 423-437.
24. S. Katayama, Y. Tomaru, T. Kasukawa, et al., Antisense transcription in the mammalian transcriptome, Science 309 (2005) 1564-1566.
25. M.A. Faghihi, F. Modarresi, A.M. Khalil, et al., Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase, Nat. Med. 14 (2008) 723-730.
26. M.A. Faghihi, C. Wahlestedt, Regulatory roles of natural antisense transcripts, Nat. Rev. Mol. Cell Biol. 10 (2009) 637-643.
27. P. Carninci, Y. Hayashizaki, Noncoding RNA transcription beyond annotated genes, Curr. Opin. Genet. Dev. 17 (2007) 139-144.
28. Y. Chu, X. Yue, S.T. Younger, B.A. Janowski, D.R. Corey, Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter, Nucleic Acids Res. 38 (2010) 7736-7748.
29. F. Modarresi, M.A. Faghihi, M.A. Lopez-Toledano, et al., Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation, Nat. Biotechnol. 30 (2012) 453-459.
30. W.M. Liu, W.M. Chu, P.V. Choudary, C.W. Schmid, Cell stress and translational inhibitors transiently increase the abundance of mammalian SINE transcripts, Nucleic Acids Res. 23 (1995) 1758-1765.
31. T. Kimura, S. Jiang, M. Nishizawa, et al., Stabilization of human interferon-alpha1 mRNA by its antisense RNA, Cell. Mol. Life Sci. 70 (2013) 1451-1467.
32. C. Tufarelli, J.A.S. Stanley, D. Garrick, J.A. Sharpe, et al., Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease, Nat. Genet. 34 (2003) 157-165.
33. J. Choi, A.I. Levey, S.T. Weintraub, et al., Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases, J. Biol. Chem. 279 (2004) 13256-13264.
34. C. Carrieri, L. Cimatti, M. Biagioli, et al., Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat, Nature 491 (2012) 454-457.
35. M. Kobayashi-Ishihara, M. Yamagishi, T. Hara, et al., HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period, Retrovirology 9 (2012) 38.
36. S. Saayman, A. Ackley, A.M. Turner, et al., An HIV-encoded antisense long noncoding RNA epigenetically regulates viral transcription, Mol. Ther. (2014).
37. C. Vanhée-Brossollet, H. Thoreau, N. Serpente, et al., A natural antisense RNA derived from the Hiv-1 Env gene encodes a protein which is recognized by circulating antibodies of Hiv+ individuals, Virology 206 (1995) 196-202.
38. M. Matsuoka, P.L. Green, The HBZ gene, a key player in HTLV-1 pathogenesis, Retrovirology 6 (2009) 71.
39. T. Zhao, M. Matsuoka, HBZ and its roles in HTLV-1 oncogenesis, Front. Microbiol. 3 (2012) 247.
40. N.L. Michael, M.T. Vahey, L. d'Arcy, et al., Negative-strand RNA transcripts are produced in human immunodeficiency virus type 1-infected cells and patients by a novel promoter downregulated by Tat, J. Virol. 68 (1994) 979-987.
41. A.R. Gruber, R. Lorenz, S.H. Bernhart, et al., The vienna RNA website, Nucleic Acids Res. 36 (2008) W70-W74.
42. B.J. Poiesz, F.W. Ruscetti, A.F. Gazdar, et al., Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 7415-7419.
43. T. Uchiyama, J. Yodoi, K. Sagawa, et al., Adult T-cell leukemia: clinical and hematologic features of 16 cases, Blood 50 (1977) 481-492.
44. D. Larocca, L.A. Chao, M.H. Seto, T.K. Brunck, Human T-cell leukemia virus minus strand transcription in infected T-cells, Biochem. Biophys. Res. Commun. 163 (1989) 1006-1013.
45. G. Gaudray, F. Gachon, J. Basbous, et al., The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription, J. Virol. 76 (2002) 12813-12822.
46. J. Arnold, B. Zimmerman, M. Li, M.D. Lairmore, P.L. Green, Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation, Blood 112 (2008) 3788-3797.
47. Y. Satou, J. Yasunaga, M. Yoshida, M. Matsuoka, HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells, Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 720-725.
48. C. Daly, N.C. Reich, Double-stranded RNA activates novel factors that bind to the interferon-stimulated response element, Mol. Cell. Biol. 13 (1993) 3756-3764.
49. C.A. Stein, The experimental use of antisense oligonucleotides: a guide for the perplexed, J. Clin. Invest. 108 (2001) 641-644.
50. J.C. van Deutekom, G.J. van Ommen, Advances in Duchenne muscular dystrophy gene therapy, Nat. Rev. Genet. 4 (2003) 774-783.
51. H. Sierakowska, M.J. Sambade, S. Agrawal, R. Kole, Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides, Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 12840-12844.
52. K. Siva, G. Covello, M.A. Denti, Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases, Nucleic Acid Ther. 24 (2014) 69-86.
53. R.T. Hillman, R.E. Green, S.E. Brenner, An unappreciated role for RNA surveillance, Genome Biol. 5 (2004) R8.
54. A. Aartsma-Rus, G.J. van Ommen, Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications, RNA 13 (2007) 1609-1624.
55. P. Lorenz, B.F. Baker, C.F. Bennett, D.L. Spector, Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies, Mol. Biol. Cell 9 (1998) 1007-1023.
56. G.B. Mulamba, A. Hu, R.F. Azad, et al., Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922), Antimicrob. Agents Chemother. 42 (1998) 971-973.
57. R.S. Geary, S.P. Henry, L.R. Grillone, Fomivirsen: clinical pharmacology and potential drug interactions, Clin. Pharmacokinet. 41 (2002) 255-260.
58. M. Manoharan, 20′-Carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation, Biochim. Biophys. Acta 1489 (1999) 117-130.
59. A. Amantana, P.L. Iversen, Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers, Curr. Opin. Pharmacol. 5 (2005) 550-555.
60. W.H. Pan, G.A. Clawson, Antisense applications for biological control, J. Cell. Biochem. 98 (2006) 14-35.
61. A.G. Douglas, M.J. Wood, Splicing therapy for neuromuscular disease, Mol. Cell. Neurosci. 56 (2013) 169-185.
62. J. Kurreck, E. Wyszko, C. Gillen, V.A. Erdmann, Design of antisense oligonucleotides stabilized by locked nucleic acids, Nucleic Acids Res. 30 (2002) 1911-1918.
63. A. Sanchez, M.P. Kiley, B.P. Holloway, D.D. Auperin, Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus, Virus Res. 29 (1993) 215-240.
64. A. Sanchez, M.P. Kiley, Identification and analysis of Ebola virus messenger RNA, Virology 157 (1987) 414-420.
65. K.L. Warfield, D.L. Swenson, G.G. Olinger, et al., Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers, PLoS Pathog. 2 (2006) e1.
66. D.L. Swenson, K.L. Warfield, T.K. Warren, et al., Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection, Antimicrob. Agents Chemother. 53 (2009) 2089-2099.
67. T.K. Warren, K.L. Warfield, J. Wells, et al., Advanced antisense therapies for postexposure protection against lethal filovirus infections, Nat. Med. 16 (2010) 991-994.
68. N. Dias, C.A. Stein, Antisense oligonucleotides: basic concepts and mechanisms, Mol. Cancer Ther. 1 (2002) 347-355.
69. M. Noguchi, H. Yi, H.M. Rosenblatt, et al., Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans, Cell 73 (1993) 147-157.
70. M. Cavazzana-Calvo, S. Hacein-Bey, C.D. Basile, et al., Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science 288 (2000) 669-672.
71. S. HaceinBey, M. CavazzanaCalvo, F. LeDeist, et al., Gamma c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function, Blood 87 (1996) 3108-3116.
72. J. Chinen, J. Davis, S.S. De Ravin, et al., Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency, Blood 110 (2007) 67-73.
73. S. Hacein-Bey-Abina, F. Le Deist, F. Carlier, et al., Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy, N. Engl. J. Med. 346 (2002) 1185-1193.
74. S. Hacein-Bey-Abina, A. Garrigue, G.P. Wang, et al., Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1, J. Clin. Invest. 118 (2008) 3132-3142.
75. E. Marshall, Gene therapy: second child in French trial is found to have leukemia, Science 299 (2003). pp. 320-320.
76. D.B. Kohn, M. Sadelain, J.C. Glorioso, Occurrence of leukaemia following gene therapy of X-linked SCID, Nat. Rev. Cancer 3 (2003) 477-488.
77. K. Takahashi, K. Tanabe, M. Ohnuki, et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell 131 (2007) 861-872.
78. K. Takahashi, S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell 126 (2006) 663-676.
79. L. Warren, P.D. Manos, T. Ahfeldt, et al., Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA, Cell Stem Cell 7 (2010) 618-630.
80. E.M. Chan, S. Ratanasirintrawoot, I.H. Park, et al., Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells, Nat. Biotechnol. 27 (2009) 1033-1037.
81. I.H. Park, R. Zhao, J.A. West, et al., Reprogramming of human somatic cells to pluripotency with defined factors, Nature 451 (2008) 141-146.
82. M.S. Kormann, G. Hasenpusch, M.K. Aneja, G. Nica, et al., Expression of therapeutic proteins after delivery of chemically modified mRNA in mice, Nat. Biotechnol. 29 (2011) 154-157.
83. L. Zangi, K.O. Lui, A. von Gise, et al., Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction, Nat. Biotechnol. 31 (2013) 898-907.
84. E. Tambuyzer, Rare diseases, orphan drugs and their regulation: questions and misconceptions, Nat. Rev. Drug Discov. 9 (2010) 921-929.
85. K. Sato, M. Hamada, K. Asai, T. Mituyama, CENTROIDFOLD: a web server for RNA secondary structure prediction, Nucleic Acids Res. 37 (2009) W277-W280.
86. D.H. Mathews, J. Sabina, M. Zuker, D.H. Turner, Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure, J. Mol. Biol. 288 (1999) 911-940.
87. Y. Wan, K. Qu, Q.C. Zhang, et al., Landscape and variation of RNA secondary structure across the human transcriptome, Nature 505 (2014) 706-709.
88. S. Rouskin, M. Zubradt, S. Washietl, et al., Genome-wide probing of RNA structure reveals active unfolding of mRNA structures in vivo, Nature 505 (2014) 701-705.
89. A. Ben-Shem, N.G. de Loubresse, S. Melnikov, et al., The structure of the eukaryotic ribosome at 3.0 angstrom resolution, Science 334 (2011) 1524-1529.
90. Y. Wan, K. Qu, Q.C. Zhang, et al., Landscape and variation of RNA secondary structure across the human transcriptome, Nature 505 (2014) 706-709.
91. S.A. Mortimer, M.A. Kidwell, J.A. Doudna, Insights into RNA structure and function from genome-wide studies, Nat. Rev. Genet. 15 (2014) 469-479.
92. R. Kole, A.R. Krainer, S. Altman, RNA therapeutics: beyond RNA interference and antisense oligonucleotides, Nat. Rev. Drug Discov. 11 (2012) 125-140.